Lts Lohmann Therapie-systeme Ag

Lts Lohmann Therapie-systeme Gmbh

Lts Lohmann Therapie-systeme Gmbh + Co. Kg

Other

Eli Lilly and Company

Merck Patent Gmbh

Purdue Pharma L.p.

Beiersdorf Ag

Gruenenthal Gmbh

Nupathe Inc.

Photonamic Gmbh & Co. Kg

Lts Lohmann Therape-system Ag

Grunenthal Gmbh

Ucb Pharma Gmbh

Fritz Herrmann

Michael Horstmann

Wolfgang Laux

Mohammad Sameti

Horst Dzekan

Bodo Asmussen

Walter Mueller

Gerd Hoffmann

Christoph Schmitz

Sandra Wiedersberg

Reinhold Meconi

Patrick Mohr

Andreas Koch

Peter Steinborn

Karin Ludwig

Tobias Jung

Thomas Hille

Walter Muller

Steven Minh Dinh

Klaus Schumann

Frank Seibertz

Hans-Rainer Hoffmann

Harlan E Shannon

Terri Sebree

Peter Lell

Stefan Bracht

Walter Müller

Kai K&ouml;pke

Marion Kursawe

Yves-Thorsten Przybylla

Rainer Lichtenberger

Paul M Gargiulo

Henricus L G M Tiemessen

René Eifler

Johannes Josef Leonhard

Uwe Wortmann

Gunter Guse

Hans R Hoffmann

Robert-Peter Klein

Walter M&uuml;ller

Eric Galia

Heinrich Kindel

Lisa A Shipley

Rolf Pracht

Frank Theobald

Hanshermann Franke

Kirti H Valia

Regine Kaufmann

Jan Stampfuss

Tobias Kleudgen

Wolfgang Prange

Axel Erler

Sylvia Hahn

Robert-Pieter Klein

Franklin Porter Bymaster

Katja Zinndorf

Christian Hausen

Christina Schütz

Roman Hadaschik

Susanne Stoelben

Klaus Pusecker

Stefan Buller

Stefan Hungerbach

Rene Eifler

The invention relates to a transdermal therapeutic system for the controlled release of water-soluble pharmaceutical active ingredients from an aqueous phase, comprising an occlusive back layer, a central device facing the skin for releasing the agent, an adhesive layer concentrically surrounding the dispensing device and a removable protective film. Said device is made from a stationary solid phase and a liquid phase containing the active ingredient in aqueous solution, the solid phase being formed from a solid with a fleecy or spongy structure.

Transdermal therapeutic system for administering water-soluble peptides and polypeptides

Adhesive bandages are provided with a water-vapor permeable back layer and an adhesive layer, in which the adhesive layer includes 10 weight percent of a disperse internal phase of hydrophilic particles that are water-swellable in an outer phase that includes at least 10 weight percent of a styrene block copolymer and at least 20 weight percent of an ester resin of colophony, and that can further contain at least one anti-virus substance.

Water-vapor-permeable adhesive bandages

A composition for transdermal delivery, particularly iontophoretic transdermal delivery, having at least one cationic active agent or a salt thereof. The composition comprises at least one cationic active agent or a salt thereof, at least one polyamine and/or polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. Use of the composition as a component of a transdermal patch or of an iontophoretic transdermal patch is also provided, as well as the use of the composition in a method for transdermally or iontophoretically administering cationic active agents. A method for determining the in vitro skin permeation properties of an active agent-containing iontophoretic composition is also provided.

Composition for transdermal delivery of cationic active agents

The invention relates to a composition for transdermal delivery, particularly iontophoretic transdermal delivery, of at least one cationic active agent or a salt thereof. The composition includes at least one cationic active agent or a salt thereof, at least one polyamine or/and polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. The invention further relates to the use of such composition as a component of a transdermal patch or of an iontophoretic transdermal patch, as well as to the use of such composition in a method for transdermally and/or iontophoretically administering cationic active agents. The invention further includes methods for determining the in vitro skin permeation properties of an active-agent-containing iontophoretic composition.

The invention relates to a transdermal therapeutic system (TTS) which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system incorporates a back layer and an active substance-containing layer that includes at least one peptide and a carrier substance.

Transdermal therapeutic system for the administration of peptides

The present invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles.

Transdermal therapeutic system comprising active ingredient particles and having increased active ingredient flux

The invention relates to a transdermal therapeutic system (TTS), which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system includes a back layer and an active substance-containing layer that contains at least one peptide and a carrier substance, preferably as a textile web material.

The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.

Transdermal administration of memantine

A device with a positioning frame which can be adhered onto the skin and with a transdermal therapeutic system which can be inserted into a cut-out that passes through the positioning frame. The active substance dispensing outlet side of the inserted transdermal therapeutic system facing the skin. The device includes a tool unit which can be inserted into the cut-out of the positioning frame and centered in said cut-out in order to produce openings at least in the uppermost layer of the skin.

Device with transdermal therapeutic system, and positioning aid and penetration aid

The invention relates to a transdermal therapeutic system, comprising a back layer that is impermeable to an active ingredient, a polymer matrix containing the active ingredient, and a protective layer that can be pulled off, wherein 5-aminolevulinic acid hydrochloride is used as the active ingredient and the basic polymer of the polymer matrix is an adhesive polyacrylate. Said transdermal therapeutic system is suitable for diagnosing and treating preliminary stages of skin cancer, such as actinic keratosis, and oncological skin diseases.

Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride

The invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles.

A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer-based layer which is remote from the skin with a rate of application of at least 80 g/m, and an adhesive skin-contact layer which is adjacent to the polymer-based layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m. The at least one active pharmaceutical ingredient is present in both the polymer-based layer remote from the skin and the skin-contact layer.

Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy

A transdermal therapeutic system for administering at least one active pharmaceutical ingredient, including a polymer layer which is remote from the skin and is based on polyisobutylenes with a rate of application of at least 80 g/m, and an adhesive skin-contact layer which is adjacent to the polymer layer remote from the skin and is based on acrylate copolymers with a rate of application of not more than 50 g/m. The at least one active pharmaceutical ingredient is present in both the layer remote from the skin and the skin-contact layer.

The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerably increased utilization of the active substance.

Transdermal therapeutic system for administering the active substance buprenorphine

Growing community of inventors

Neuwied, Germany

Michael Horstmann